MDLN.US Medline Inc. Class A Common Stock
- Market cap
- USD 51.9B
- P/E
- 89.7x
- P/B
- 2.94x
- ROE
- 4.3%
- Dividend yield
- 1.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MDLN.US undervalued?
Graham numberThe Graham number of Medline Inc. Class A Common Stock cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medline Inc. Class A Common Stock fundamental analysis
No fundamental analysis for Medline Inc. Class A Common Stock yet.
Medline Inc. Class A Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medline Inc. Class A Common Stock
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg p…
Full company profileMedline Inc. Class A Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medline Inc. Class A Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 21.4B | 23.2B | 25.5B | 28.4B | 30.5B |
| Gross Profit | 4.56B | 5.22B | 6.29B | 7.52B | 7.74B |
| Operating Income | 870M | 1.44B | 2.23B | 2.21B | 1.76B |
| EBITDA | 1.85B | 2.59B | 3.53B | 2.26B | 2.87B |
| Net Income | -25.0M | 234M | 1.20B | 1.16B | 512M |
| EPS | -0.03 | 0.30 | 1.52 | 1.43 | 0.39 |
| Balance Sheet | |||||
| Total Assets | - | 36.1B | 36.0B | 38.5B | 40.2B |
| Total Liabilities | - | 19.1B | 19.5B | 19.2B | 20.8B |
| Shareholders' Equity | - | 17.0B | 16.5B | 10.7B | 11.8B |
| Cash & Short-term Investments | - | 1.59B | 250M | 1.94B | 3.61B |
| Total Debt | - | 16.8B | 16.9B | 12.6B | 12.6B |
| Cash Flow | |||||
| Operating Cash Flow | 187M | 1.69B | 1.77B | 1.74B | 2.87B |
| Capital Expenditure | 254M | 285M | 364M | 447M | 464M |
| Free Cash Flow | -67.0M | 1.40B | 1.41B | 1.30B | 2.41B |
| Ratios | |||||
| ROE | - | 1.4% | 7.3% | 10.8% | 4.3% |
| ROA | - | 0.6% | 3.3% | 3.0% | 1.3% |
| Net Profit Margin | -0.1% | 1.0% | 4.7% | 4.1% | 1.7% |
| Debt to Equity | - | 0.99x | 1.02x | 1.17x | 1.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medline Inc. Class A Common Stock dividends
- Dividend yield
- 1.00%
- Forward dividend
- -
- Payout ratio
- 44.7%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 518M | 0.64 | 44.7% |
| 2024 | - | - | - |
| 2023 | USD 114M | 0.14 | 48.7% |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medline Inc. Class A Common Stock
- Insiders 1.20%
- Institutions 98.80%
- Public & others 0.00%
- Shares outstanding 879M
- Free float 382M
Top funds holding MDLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds AMCAP A | 18.8M | 2.14% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 18.1M | 2.06% | +45.72% | Sep 2026 |
| Fidelity Contrafund | 14.6M | 1.66% | +8.85% | Sep 2026 |
| American Funds Growth Fd of Amer A | 13.9M | 1.58% | +53.84% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 12.2M | 1.39% | +44.47% | Sep 2026 |
| MFS Value A | 6.66M | 0.76% | -2.89% | Sep 2026 |
| Janus Henderson Forty S | 5.91M | 0.67% | 0.00% | Sep 2026 |
| Vanguard MStar Value Index Investor | 5.43M | 0.62% | +45.60% | Sep 2026 |
| American Funds IS® Growth-Income 1 | 5.25M | 0.60% | +275.44% | Sep 2026 |
| American Funds Invmt Co of Amer A | 4.24M | 0.48% | -18.61% | Sep 2026 |
| Principal MidCap R5 | 4.24M | 0.48% | +96.36% | Sep 2026 |
| Janus Henderson Enterprise D | 4.18M | 0.48% | +32.19% | Sep 2026 |
| MFS Growth B | 4.04M | 0.46% | -0.55% | Sep 2026 |
| Vanguard US Growth Investor | 3.79M | 0.43% | +12.99% | Sep 2026 |
| MS INVF US Advantage I | 3.57M | 0.41% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Value ETF | 3.56M | 0.41% | +40.74% | Sep 2026 |
| UniGlobal Vorsorge | 3.30M | 0.38% | 0.00% | Sep 2026 |
| American Funds Cptl Wld Gr&Inc A | 3.21M | 0.36% | -5.05% | Sep 2026 |
| BlackRock Mid-Cap Growth Equity Instl | 3.12M | 0.35% | -6.76% | Sep 2026 |
| Fidelity Contrafund K6 | 3.07M | 0.35% | +8.99% | Sep 2026 |
Top institutions holding MDLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| The Carlyle Group Inc | 187M | 21.28% | 0.00% | Jun 2026 |
| H&F Corporate Investors X, Ltd. | 70.9M | 8.06% | -18.04% | Jun 2026 |
| Capital Research Global Investors | 47.8M | 5.43% | +19.50% | Sep 2026 |
| FMR Inc | 47.0M | 5.34% | +28.47% | Jun 2026 |
| Amvescap Plc. | 38.3M | 4.36% | +82.92% | Jun 2026 |
| BlackRock Inc | 26.4M | 3.00% | +55.96% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 21.6M | 2.46% | +37.59% | Jun 2026 |
| Lone Pine Capital LLC | 21.0M | 2.39% | +77.86% | Jun 2026 |
| Massachusetts Financial Services Company | 19.9M | 2.26% | +71.91% | Jun 2026 |
| Vanguard Capital Management, LLC | 17.8M | 2.03% | +20.95% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 16.8M | 1.91% | +18.59% | Jun 2026 |
| Egerton Capital LLP | 16.5M | 1.87% | +277.27% | Jun 2026 |
| Jupiter Topco LLC | 15.9M | 1.80% | 0.00% | Jun 2026 |
| DZ BANK AG Deutsche Zentral-Genossenschaftsbank Frankfurt am Main | 12.0M | 1.36% | +172.69% | Jun 2026 |
| Baillie Gifford & Co Limited. | 11.2M | 1.28% | -0.94% | Sep 2026 |
| NORGES BANK | 8.48M | 0.96% | +69.51% | Jun 2026 |
| State Street Corp | 8.45M | 0.96% | +75.16% | Jun 2026 |
| Geode Capital Management, LLC | 7.95M | 0.90% | +27.01% | Jun 2026 |
| SurgoCap Partners LP | 7.49M | 0.85% | +23.25% | Jun 2026 |
| WCM Investment Management | 7.40M | 0.84% | +2.48% | Jun 2026 |
Medline Inc. Class A Common Stock company profile
- Company name
- Medline Inc. Class A Common Stock
- Ticker
- MDLN.US
- Exchange
- USA Stocks
- Listed since
- Dec 17, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 45,000
- Fiscal year end
- December
- Address
- 3 Lakes Drive, Northfield, IL, United States, 60093
- Phone
- 847 949 5500
- Website
- medline.com
About Medline Inc. Class A Common Stock
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
Medline Inc. Class A Common Stock management
10- Mr. James M. BoyleCEO & Director · born 1972
- Mr. Michael B. DrazinChief Financial Officer · born 1975
- Mr. Douglas P. GolwasChief Commercial Officer · born 1969
- Ms. Jessi L. CorcoranChief Accounting Officer · born 1983
- Mr. Marshall LancasterChief Information Officer
- Ms. Karen M. KingGlobal Head Investor Relations
- Mr. Alex M. LibermanChief Legal Officer · born 1965
- Mr. Ben FoxVice President of Corporate Communications
- Ms. Jenny LeeChief Marketing Officer
- Mr. Christopher P. ShryockChief Human Resources Officer · born 1982